MRL-lpr/lpr mice spontaneously develop a severe autoimmune syndrome, characterized by massive generalized lymphadenopathy, arthritis, arteritis, dermatitis and immune complexmediated glomerulonephritis. Bone marrow transplantation (BMT) from MHC-matched systemic lupus erythematosus (SLE)-resistant donors to susceptible recipients has proved effective in correcting autoimmune manifestations in autoimmune-prone mice. We investigated the effect of syngeneic BMT from MRL/lpr (donor) to immunocompromised MRL/lpr (recipient), after purging the bone marrow inoculum with MoAbs against mature T cells (anti-Thy 1.2). All the untreated mice developed lymphadenopathy and by the age of 36 weeks five of the eight were dead; in contrast, all the mice which underwent syngeneic BMT following acute immunosuppression with total body irradiation (900 cGy) (TBI) remained disease-free. In an additional experiment, it was found that conditioning with cyclophosphamide (CY) before BMT was more effective than TBI in inhibiting delayed-onset autoimmune manifestations (mean survival 350 days in the CY group and 305 days in the TBI group, versus 197 days in untreated controls). Under both immunosuppressive regimens T cell-depleted bone marrow grafts produced far better results than did unmanipulated BMT. Following syngeneic BMT the incidence of proteinuria and the level of serum anti-DNA (dd) antibodies were significantly reduced, compared with that of the agematched untreated controls. CY was more effective than TBI in reducing the anti-DNA titres. Likewise, T depletion of bone marrow inocula before BMT induced a more drastic drop in autoantibodies, following both CY and TBI conditioning protocols. After syngeneic BMT (either CY or TBI) no signs of lymphadenopathy were observed even at an advanced age. Upon histopathological examination, the BMT-treated mice displayed normal glomeruli with occasional minimal signs of glomerulonephritis. Syngeneic T cell-depleted BMT following acute cytoreduction of anti-self immune lymphocytes may represent a new therapeutic approach for drug-resistant autoimmune diseases.
INTRODUCTION
MRL/Mp-lpr/lpr (MRL/lpr) mice spontaneously develop a severe systemic lupus erythematosus (SLE)-like autoimmune syndrome, characterized by massive generalized lymphadenopathy (due to expression of the lpr gene), arthritis, arteritis, dermatitis and immune complex-mediated glomerulonephritis [1] [2] [3] . Serologic 
abnormalities include
Correspondence: Dimitrios Karussis hypergammaglobulinaemia, production of autoantibodies (anti-DNA) and rheumatoid factor and the formation of immune complexes. Glomerulonephritis and eventually renal insufficiency (proteinuria with inflammatory precipitates and uraemia) are usually observed at the late stages of the disease. The MRL/lpr mice may, therefore, be regarded as an animal model for human SLE. Various non-specific, anti-inflammatory and immunosuppressive agents have been used for the treatment of SLE. Long-term maintenance treatment is usually required, resulting in cumulative, occasionally severe, side effects, without significantly altering the natural course of the disease [4] [5] [6] .
Experimental therapeutic approaches with acute and more aggressive immunosuppression achieved by high-dose lymphoid irradiation (TLI) or sublethal total body irradiation (TBI) have proved effective in MRL/lpr and NZB mice [7] [8] [9] . Although the use of TLI exerts an ameliorative effect on autoimmune diseases [10, 11] , the attendant risks of ionizing irradiation preclude its application (as single treatment). Bone marrow transplantation (BMT), from MHC-matched SLEresistant donors into susceptible recipients, corrected many of the autoimmune manifestations in the early life of the autoimmune-prone mice [12] . Theofilopoulos et al. [12] demonstrated that bone marrow and spleen cell transplants from MRL+/+ mice (a strain congenic to MRL/lpr with 99-6% genome identity except for the lpr gene), which exhibit only mild signs of autoimmunity, to lethally irradiated MRL/lpr recipients, significantly prolonged survival and suppressed lymphadenopathy and splenomegaly. Marked anti-autoimmune effects were also documented following successful allogeneic BMT from normal donors to SLE-prone recipients [13] .
Recent clinical observations have shown that the autoimmune manifestations are ameliorated in cancer patients undergoing allogeneic BMT, due to replacement of the immunohaematopoietic compartment system with healthy stem cells [14] [15] [16] . Unfortunately, the use of allogeneic BMT in autoimmune diseases is not justified in view of the attendant major procedure-related risks, including infections, haemorrhage and graft-versus-host disease. In addition, one is unlikely to find matched donors for the majority of patients.
In view of recent reports by our own team [17] [18] [19] as well as other investigators [20, 21] attesting to the successful results of high dose chemotherapy or TBI followed by syngeneic BMT in the reversal of experimentally induced autoimmunity, it seemed worthwhile to explore a similar approach in spontaneously occurring autoimmunity (SLE) in genetically susceptible mouse strains.
We therefore tested the effect of syngeneic BMT from MRL/lpr (donor) to immunocompromised MRL/lpr (recipient), after purging bone marrow inocula with MoAbs against mature T cells (T cell depletion). This therapeutic approach resembles autologous T-depleted BMT in humans, a procedure with mild side effects. The long term survival, as well as the serological and pathological evidence of ameliorated disease in mice treated with syngeneic BMT, could encourage the implementation of high-dose chemoradiotherapy protocols followed by autologous BMT in treatment of life-threatening human autoimmune diseases.
MATERIALS AND METHODS Mice
Female and male MRL/lpr and MRL+/+ mice obtained from E. Murphy (Jackson Laboratory, Bar Harbor, ME) were bred and maintained at the Weizmann Institute mouse colony, under standard conditions. Mice were housed in top filtered cages, fed a regular diet and given acidified water without antibiotics.
Total body irradiation
The mice were positioned in radiation chambers and exposed to a single dose of 900 cGy TBI from a Gamma beam 1 50-A6°Co source (Atomic Energy of Canada, Kanata, Ontario). The skin to source distance (SSD) was 105 cm and the dose rate was 65 cGy/min. This dose proved lethal in 80-100% of the MRL/ lpr mice not reconstituted with syngeneic bone marrow cells. Cyclophosphamide Cyclophosphamide (CY; Taro, Israel) was freshly dissolved in water and administered as a single i.v. dose of 300 mg/kg body weight, 36-48 h before BMT.
Syngeneic bone marrow transplantation
Bone marrow cells were obtained from MRL/lpr mice by flushing femora and humora with a 25 G needle connected to a syringe containing RPMI 1640 medium. The bone marrow inoculum was either enriched with spleen cells (2-4 x 106/ mouse) obtained from MRL/lpr mice, or depleted of mature T lymphocytes (TCD), as follows. Donor bone marrow cells were treated with the MoAb anti-Thy 1.2 (Cedarlane Laboratories, Hornby, Ontario, Canada). They were then resuspended at 107/ml in diluted MoAb anti-Thy 1.2 (1: 300) and incubated for 30 min at 4°C with occasional agitation, washed and pelleted. Low-Tox rabbit complement (Cedarlane Laboratories) was added at a final dilution of 1: 10 and the cells were incubated for a further 60 min at 37°C, pelleted, resuspended and injected intravenously into the tail vein of the recipients. Cell recovery was calculated; viability was determined by trypan blue exclusion. Cells (10-20 x 106) were then injected intravenously into the tail vein of syngeneic recipients. The lytic efficacy of the antibody was monitored by testing the residual T cells with FITC-conjugated anti-Thy 1.2 MoAb (Bio Yeda, Rehovot, Israel). More than 95% of T cells in the bone marrow inocula were consistently killed.
Assessment ofproteinuria
Proteinuria was determined using a commercial urinalysis Multisix paper impregnated with tetrabromphenol blue at pH 3 0. The protein concentrations in the urine were graded according to a scale of 0 to 4 as follows: 0, 0-30 mg/dl; 1, 30-lOOmg/dl; 2, 100-300mg/dl; 3, 300-lOOOmg/dl; and 4, >1000 mg/dl. Measurement of anti-double stranded (native) DNA (dsDNA) Antibodies to dsDNA (native) were measured in a nitrocellulose Millipore filter assay as previously described [22] . Ten micrograms of the radioactive antigen 3H-DNA (New England Nuclear, Boston, MA), were incubated with 10tl of undiluted serum from individual animals, 100 1L of 0-2M borate-buffered saline pH 8-0, 0-15 M NaCl for 30 min at 37°C followed by overnight incubation at 4°C. The antigen-antibody suspensions were then passed through a 0-45-tim nitrocellulose Millipore filter under suction and washed four times in 3 ml PBS. Radioactivity was determined in a liquid scintillation counter. The results are expressed as per cent binding activity of corrected ct/min retained on the filter.
RESULTS
Effect of treatment of MRL/lpr mice with high dose CY or TBI followed by syngeneic or congenic BMT on disease-associated mortality In the first set of experiments, female MRL/lpr mice were Age (weeks) Fig. 1 . Systemic lupus erythematosus (SLE)-associated mortality in MRL/lpr mice treated with total body irradiation (TBI) followed by syngeneic BMT. Female MRL/lpr mice were treated at 9 weeks with TBI (900cGy). One day later they were injected with 10 x 106 bone marrow cells obtained from syngeneic female MRL/lpr donors of the same age, after in vitro depletion of the mature T cells with an anti-Thy Female MRL/lpr mice were treated at the age of 10 weeks with either TBI (900cGy) or CY (300mg/kg) followed by SBMT, using bone marrow cells obtained from age-matched male MRL/lpr donors supplemented with 4 x 106 syngeneic spleen cells. All mice were followed up for over 12 months. 0, Untreated MRL/lpr; A, TBI+SBMT (+spleen cells); *, CY+SBMT (+spleen). treated at 9-10 weeks of age with TBI (900 cGy). One day later they were injected with 10 x 106 bone marrow cells obtained from syngeneic female MRL/lpr donors of the same age, after in vitro depletion of the mature T cells with an anti-Thy 1.2 MoAb and complement, or from non-TCD congenic MRL/ +/+. Development of the autoimmune syndrome in untreated and TBI+SBMT-treated animals, as indicated by the rate of disease-associated mortality, is depicted in Fig. 1 . By the age of 36 weeks, five of the eight untreated mice had died, whereas all eight TBI+SBMT-treated animals remained alive with no signs of disease. Survival was similar in mice which had received BMT (TCD) from MRL/lpr and MRL/+/+ donors ( Fig. 1) . At this point all animals were killed and histopathological studies were performed.
In a second set of experiments, female MRL/lpr mice were similarly treated with either TBI (900 cGy) or CY (300 mg/kg) followed by SBMT, using bone marrow cells obtained from agematched male MRL/lpr donors. In half of the mice, 4 x 106 syngeneic spleen cells were added to each bone marrow inoculum in order to mimic human unmanipulated BMT, in which the bone marrow cells are usually contaminated with peripheral blood lymphocytes. The other recipients received T cell-depleted bone marrow cells. All mice were followed up for over 12 months. As can be seen in Figs 2 and 3, conditioning with CY rather than TBI, before SBMT, was more effective in prolonging disease-free survival due to greater inhibition of delayed-onset autoimmune manifestations. In both immunosuppressive regimens (CY or (Fig. 4 ). At 7 months of age, proteinuria could be detected in a minority of mice in all the treated groups, whereas nearly all the surviving untreated controls were proteinuric.
Serum anti-DNA antibodies The level of serum anti-DNA (ds) antibodies was significantly reduced in mice treated with TBI+BMT (P<0 01) (Fig. 5a ). The decrease, already evident 2 months after BMT (at the age of 4-5 months) and maintained until the time of sacrifice (6 months) was similar to the reduced anti-DNA titre observed in MRL/lpr mice treated with TCD or T cell-enriched SBMT from MRL/+/+ donors (Fig. 5a ). In an additional experiment, S>* the effect of different immunosuppressive regimens (CY or TBI) on anti-DNA antibody levels was compared (Fig. 5b ). As can be seen, CY was more effective than TBI in reducing anti-DNA titres; T cell depletion of the bone marrow inoculum resulted in Age (months) a more drastic reduction in autoantibody level, following both CY and TBI protocols (Fig. 5b) . These effects were more Fig. 4 . Incidence of proteinuria in MRL/lpr mice treated with cyclophosphamide (CY) or total body irradiation (TBI) followed by SBMT. Urine samples were examined at various intervals for the presence ofproteinuria with a commercial urinalysis Multistix paper. Urinary protein concentration was graded according to a 0-4 scale, as described in Materials and Methods. Samples containing >300 mg/dl protein were considered positive. 0, Untreated MRL/lpr; A, TBI+SBMT+spleen; El, TBI+SBMT (TCD); 0, CY+SBMT+spleen; A, CY+SBMT (TCD).
TBI), T cell-depleted bone marrow cells produced better results than those obtained with T cell-enriched SBMT ( Fig. 3 ; data shown only for CY). Although all animals in the CY+SBMT (TCD) group survived at least 2 months after those in the T cellenriched group had already started to die, the 50% mortality was similar in the two groups. This late (and accelerated) mortality of the SBMT-TCD-treated mice could be attributed to infections, since some of the mice appeared cachectic. In all the groups the SBMT-treated mice ultimately developed autoimmune signs (albeit milder than in the untreated controls) and died, after a delay of 16-38 weeks (Figs 2 and 3) . A median survival of 24 weeks was recorded in the untreated mice, 40 weeks in the TBI/ SBMT+spleen group, 45 weeks in the TBI/SBMT-TCD group, 48 weeks in the CY/SBMT+spleen group and 49 weeks in the CY/SBMT-TCD group. Early (first month post-SBMT), non-SLE-related mortality was higher in the group receiving TCD-SBMT than in the non-T cell-depleted bone marrow recipients (data not shown).
Incidence ofproteinuria in SBMT-treated MRL/lpr mice The incidence of proteinuria in untreated MRL/lpr mice and mice treated with TBI or CY followed by SBMT with or without T cells is presented in Fig. 4 . Both SBMT regimens significantly reduced the incidence of proteinuria. Although high amounts of protein were present in the urine of most of the untreated mice at the age of 4 months, none of the SBMTtreated animals developed proteinuria after up to 5 months. At the age of 6 months, proteinuria appeared in only 20% of the TBI+SBMT (T cell-enriched) group of mice compared with 80% in the untreated controls. At that time point, none of the pronounced and reached statistical significance at the age of 40 weeks. It is possible that with time there are either mild graftversus-host (GVH) effects (male to female), or long-term tolerization resulting from SBMT treatment. The above results confirm the differential effect of the various treatments on disease-related mortality (Figs 2 and 3) . 6 months had normal size lymph nodes and spleens (mean lymph node weight in SBMT-treated mice 44-7 + 5mg versus 417-7 + 75mg in untreated controls (P < 0.0001); mean spleen weight 213-2 + 36-7mg in SBMT-treated mice versus 688-5 + 81 mg in untreated controls (P<0-001). Even in the late stages of the disease, only small lymph nodes could be palpated in SBMT-treated recipients. Characteristic dermatological SLE findings were either absent or mild in the SBMTtreated mice, even at an advanced age (data not shown).
Effect of SBMT on histological manifestations of renal disease
Untreated and TBI/BMT-TCD treated MRL/lpr mice were killed at the age of 6 months and kidney sections were examined in a 'blind' manner by a pathologist under light microscopy. In all the untreated mice, typical signs of SLE-like glomerulonephritis were recorded. Prominent pathological findings included generalized glomerular lesions with various morphological features. The glomeruli were markedly enlarged, exhibiting diffuse or segmental proliferative lesions, neutrophilic exudates, focal crescent formation, wire loop-like lesions, and giant eosinophilic hyaline deposits similar to the hyaline thrombi described in human SLE (Fig. 6a) . These lesions were defined as severe glomerulonephritis, grade 3. All eight SBMT-treated mice displayed only minimal signs (grade 1) of focal glomerulonephritis (Fig. 6b) .
Similar amelioration of the renal pathology was also noted in the CY+SBMT group. Generally the differences were of 1-2 degrees (grade 3 in the control and grade 1-2-minimal to moderate-in the treated groups.
DISCUSSION
MRL/lpr mice represent a well recognized model for SLE-like syndrome, which is characterized by massive lymphadenopathy, accompanied by autoantibody production with end stage renal manifestations of SLE [23] . Development of SLElike autoimmune syndrome is T cell-dependent, as documented by experiments involving neonatal thymectomy [24] as well as by in vivo treatment with anti-Thy 1.2 antibodies [25] . Previous studies on mice treated with ionizing irradiation, involving either TBI [12] , or TLI [26, 27] , showed that irradiation markedly suppresses T cell-dependent immune function by inducing selective T cell lymphopenia [28] . Hence, it is not surprising that significant prolongation of survival, accompanied by amelioration of all disease parameters, was reported in MRL/lpr mice treated with high-dose CY or lethal TBI. Similarly, in recently published experiments we demonstrated that complete remission and reinduction of unresponsiveness towards self could be achieved by acute immunosuppression followed by SBMT in experimentally induced autoimmune encephalomyelitis (EAE) [17] [18] [19] . Since the T cell repertoire following SBMT develops from the uncommitted stem cells, it seems reasonable that the newly regenerated T lymphocytes acquire unresponsiveness to self or to modified self antigens of the host, induced by injection of tissue-specific self antigens in Freund's complete adjuvant. This process is similar to the induction of self tolerance that occurs in the ontogeny of the immune system during fetal life.
The basis for the dramatic effect observed in our experiments following SBMT (with marrow cells obtained from congeneic strains prone to develop SLE-like manifestations) is more difficult to explain. Results of previous experiments in the mutant mouse strain CBA/KlJms-lpr'g/lprcg [29] , featuring adoptive transfer of T cell-depleted bone marrow allografts into lethally irradiated recipients, has indicated that SLE-like autoimmune syndrome can be transferred by haematopoietic stem cells alone. However, for full development of the autoimmune syndrome and lymphoproliferation in CBA/KlJms-lprCg/lprcg and in MRL/lpr mice, both lpr-BM stem cells and the specific lpr-lymphoid background are required [29] . MRL/ + recipients of MRL/lpr stem cells develop a wasting GVH-like syndrome, without evidence of lymphoproliferation. Transfer of a mixture of stem cells obtained from MRL/lpr and MRL/ +/+ results in a disease similar to that observed in the MRL/ lpr donor mice. This again suggests that the disease is mainly caused by a basic and dominant defect of the MRL/lpr haematopoietic stem cells, rather than by the absence of active down-regulation of anti-self reacting lymphocytes [7, 23, 26] . Conversely, if one eliminates MRL/lpr stem cells in the original hosts by allogeneic BMT, utilizing stem cells from normal strains, the resulting chimaeras no longer exhibit SLElike manifestations. Also in other SLE-like autoimmune mouse strains, such as (NZB x NZW) F1 [7, 8] and BXSB mice [30] , stem cell defects, rather than the 'environment,' seem to be responsible for the autoimmune syndrome. Abnormal immunoregulation by T cells, non-T cells or cytokines secreted by either cell subset cannot be ruled out as playing an important role in the outburst of autoimmunity. However, they too originate in the abnormal stem cell compartment. If one considers the basis of autoimmunity as a 'seed' and 'soil' analogy, clearly the main factor associated with development of autoimmunity in mouse strains is the 'seed,' since prevention of autoimmune manifestations in the same 'soil' can be accomplished by permanent engraftment of normal 'seeds'. Indeed, in comparison with experimentally induced autoimmunity, in which we documented permanent cure of autoimmunity and the development of complete resistance to rechallenge [17] , in the present experiments, despite the amelioration of the autoimmune parameters and the remarkable prolongation of disease-free survival, the disease eventually relapsed. It seems reasonable to assume that several parameters, in addition to the basic stem cell abnormality, are involved, since most animal strains prone to spontaneous autoimmune disease do not develop symptoms upon birth but only after several months. SLE-like manifestations in (NZB x NZW) F1 female mice may take 12 months to develop, which is half the life span of the mouse, thus allowing secondary immunological manipulation of the anti-self repertoire in order to delay further the onset of clinical signs and prolong survival. Indeed, genetically susceptible family members of patients suffering from SLE and type I diabetes, with anti-DNA and anti-islet autoantibodies, respectively, do not always develop clinical signs.
Be the mechanism as it may, our data suggest that autoimmune manifestations and survival following the onset of SLE-like disease may respond favourably to aggressive elimination of anti-self reacting lymphocytes by high dose CY or TBI. These data, further supported by the results of our previous experiments, suggest that high-dose immunosuppressive treatment in conjunction with autologous stem cell transplantation may significantly ameliorate the natural course of the disease, despite the presence of 'abnormal' stem cells. Our results may be relevant in designing new strategies for the treatment of life-threatening autoimmune diseases in humans. Instead of continuous immunosuppressive therapy, it may prove possible to use myeloablative doses of immunosuppressive modalities, combined with autologous stem cell transplantation, for pushing the biological clock back towards de novo immunoregulation. Progenitor myeloid cells with suppressive functions ('natural suppressors') [31] [32] [33] that develop following BMT could heighten the beneficial effect against autoreactive cells. Moreover, if autoimmunity in humans results from an external source (e.g. virus) which modifies 'self', it would not be inconceivable to achieve cure rather than temporary suppression of the disease. Pilot clinical trials of similar therapeutic strategies are now under way.
